Immix Biopharma, Inc. financial data

Symbol
IMMX on Nasdaq
Industry
Pharmaceutical Preparations
Location
11400 West Olympic Blvd., Suite 200, Los Angeles, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 518 % -37.3%
Debt-to-equity 26.8 % +83.8%
Return On Equity -103 % -4.81%
Return On Assets -80.9 % +5.36%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.5M shares +38.5%
Common Stock, Shares, Outstanding 27.5M shares +40.1%
Entity Public Float 28M USD +52.8%
Common Stock, Value, Issued 2.76K USD +40.1%
Weighted Average Number of Shares Outstanding, Basic 29.4M shares +58.4%
Weighted Average Number of Shares Outstanding, Diluted 29.4M shares +58.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 20M USD
Research and Development Expense 13M USD +64.9%
General and Administrative Expense 10M USD +50.7%
Operating Income (Loss) -23.1M USD -58.4%
Nonoperating Income (Expense) 1.06M USD +37.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -22M USD -54.8%
Income Tax Expense (Benefit) 38.3K USD +62.6%
Net Income (Loss) Attributable to Parent -21.9M USD -54.9%
Earnings Per Share, Basic -0.85 USD/shares +7.61%
Earnings Per Share, Diluted -0.85 USD/shares -4.35%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.7M USD +0.55%
Other Assets, Current 36.5K USD -78.1%
Assets, Current 22.8M USD +1.9%
Property, Plant and Equipment, Net 1.36M USD +3282%
Operating Lease, Right-of-Use Asset 1.01M USD
Other Assets, Noncurrent 20.4K USD -80.2%
Assets 25.1M USD +11.9%
Accounts Payable, Current 3.29M USD +110%
Employee-related Liabilities, Current 198K USD
Liabilities, Current 6.56M USD +132%
Operating Lease, Liability, Noncurrent 1.03M USD
Liabilities 7.59M USD +169%
Accumulated Other Comprehensive Income (Loss), Net of Tax 192K USD +311%
Retained Earnings (Accumulated Deficit) -70.2M USD -45.3%
Stockholders' Equity Attributable to Parent 17.6M USD -11.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 17.6M USD -10.7%
Liabilities and Equity 25.1M USD +11.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.83M USD -82.9%
Net Cash Provided by (Used in) Financing Activities 15.9M USD +13312%
Net Cash Provided by (Used in) Investing Activities -302K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 27.6M shares +40%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11.8M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 80 USD
Deferred Tax Assets, Valuation Allowance 7.63M USD +126%
Operating Lease, Liability 1.09M USD
Depreciation 3.01K USD +496%
Payments to Acquire Property, Plant, and Equipment 302K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.7M USD -53.7%
Lessee, Operating Lease, Liability, to be Paid 1.57M USD
Property, Plant and Equipment, Gross 64.5K USD 0%
Operating Lease, Liability, Current 62.7K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 153K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 148K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 479K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 158K USD
Deferred Tax Assets, Operating Loss Carryforwards 4.08M USD +113%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 87.7M USD +28.6%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 590K USD +167%
Interest Expense 98.9K USD -99.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%